H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. The Company is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, including Alzheimers disease, Bipolar disorder, depression, epilepsy, Huntingtons disease, Parkinsons disease and schizophrenia. The Companys product portfolio includes such pharmaceuticals, as Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimers disease, Azilect for the treatment of Parkinsons disease, Xenazine for the treatment of Huntingtons disease and Sabril for the treatment of epilepsy, among others. Additionally, the Company had a number of products in development phases. As of December 31, 2012, it was active through subsidiaries in 57 countries, including Argentina, Australia, Denmark, China, Russia, the United States and the United Kingdom, among others.
